Contenu - Abstracts



ESUR16, Parma


Rentsch C. et al. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy.

IBCN annual meeting, Bochum

Oral presentation

Rentsch C. et al. A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy.

17th World Conference on Lung Cancer (WCLC), Vienna


Matter-Walstra K. et al. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

58th ASH Annual Meeting, San Diego

Oral presentations

Driessen C. et al. SAKK 39/13: The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory multiple myeloma. A multicenter phase II trial SAKK 39/13.

Kimby E. et al. Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. First analysis of survival endpoints of the randomized phase-2 trial SAKK 35/10.


Drexler B. et al. Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14.

Lists of Abstracts

Abstracts_2016 [167 KB]

Abstracts_2015 [172 KB]

Abstracts_2014 [183 KB]

Abstracts_2013 [173 KB]